# Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

> **NCT06023641** · PHASE2 · RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 135 (estimated)

## Conditions studied

- Rhabdomyosarcoma

## Interventions

- **DRUG:** Vincristine
- **DRUG:** Dactinomycin
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Surgical Resection
- **PROCEDURE:** Proton beam radiation or external beam radiation or brachytherapy
- **DRUG:** Liposomal irinotecan
- **DRUG:** Vinorelbine
- **DRUG:** Temozolomide
- **DRUG:** Filgrastim, peg-filgrastim

## Key facts

- **NCT ID:** NCT06023641
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-13
- **Primary completion:** 2034-10
- **Final completion:** 2037-10
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06023641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06023641, "Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06023641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*